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Pretreatment with adalimumab reduces ventilator-
induced lung injury in an experimental model
ORIGINAL ARTICLE
INTRODUCTION
Acute respiratory distress syndrome (ARDS) is among the main indications 
for mechanical ventilation (MV); ARDS and MV a significant impact on 
public health, with mortality rates between 35% and 65%.(1,2) Although 
lifesaving, MV can also cause lung injury or aggravate pre-existing injury. This 
ventilator-induced lung injury (VILI), characterized by pulmonary edema 
and inflammation, is indistinguishable from acute lung injury (ALI) of other 
etiologies.(3) Biophysical forces are responsible for the abnormal lung physiology, 
causing a proinflammatory state.(4) The inflammatory response results in the 
release of cytokines, leukocyte recruitment to the lung parenchyma, and a 
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Objective: To determine whether 
adalimumab administration before me-
chanical ventilation reduces ventilator-
-induced lung injury (VILI).
Methods: Eighteen rats randomized 
into 3 groups underwent mechanical 
ventilation for 3 hours with a fraction of 
inspired oxygen = 0.40% including a low 
tidal volume group (n = 6), where tidal 
volume = 8mL/kg and positive end-expi-
ratory pressure = 5cmH2O; a high tidal 
volume group (n = 6), where tidal volume 
= 35mL/kg and positive end-expiratory 
pressure = 0; and  a pretreated + high 
tidal volume group (n = 6) where ada-
limumab (100ug/kg) was administered 
intraperitoneally 24 hours before mecha-
nical ventilation + tidal volume = 35mL/
kg and positive end-expiratory pressure = 
0. ANOVA was used to compare histo-
logical damage (ATS 2010 Lung Injury 
Scoring System), pulmonary edema, 
lung compliance, arterial partial pressu-
re of oxygen, and mean arterial pressure 
among the groups.
Results: After 3 hours of ventila-
tion, the mean histological lung in-
jury score was higher in the high tidal 
volume group than in the low tidal 
volume group (0.030 versus 0.0051, 
respectively, p = 0.003). The high ti-
dal volume group showed diminished 
lung compliance at 3 hours (p = 0.04) 
and hypoxemia (p = 0,018 versus con-
trol). Pretreated HVt group had an 
improved histological score, mainly 
due to a significant reduction in leu-
kocyte infiltration (p = 0.003).
Conclusion: Histological exami-
nation after 3 hours of injurious ven-
tilation revealed ventilator-induced 
lung injury in the absence of measura-
ble changes in lung mechanics or oxy-
genation; administering adalimumab 
before mechanical ventilation reduced 
lung edema and histological damage.
ABSTRACT
Keywords: Adalimumab/administration 
& dosage; Respiration, artificial; Respi-
ratory failure; Ventilator-induced lung 
injury
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marked increase in vascular permeability, which trigger 
pulmonary edema and surfactant dysfunction, leading 
to decreased respiratory system compliance (CL) and 
impaired gas exchange.(5-8)
Lung-protective ventilation strategies based on using a 
low tidal volume (Vt) can reduce but not eliminate the risk 
of VILI.(9-11) These strategies are associated with decreased 
mortality in patients with ARDS.(12) Other strategies 
to attenuate lung inflammation may also help reduce 
VILI. The proinflammatory cytokine tumor necrosis 
factor alpha (TNF-α) has been consistently implicated 
in the pathogenesis of VILI in both experimental and 
clinical studies.(13-17) Moreover, neutrophil recruitment is 
substantially attenuated in TNF-α receptor-knockout mice 
and in mice treated with an intratracheally administered 
anti-TNF-α antibody.(16)
Adalimumab is a fully human monoclonal antibody 
(anti-TNF IgG1) that specifically binds to soluble and 
transmembrane TNF-α with high affinity, neutralizing the 
biological function of TNF-α by blocking its interaction 
with the cell surface receptors p55 and p75 TNF-α. 
Binding of antibodies with transmembrane TNF-α 
induces an intracellular signaling cascade that results 
in the release of intracellular calcium, the production 
of cytokines, and the expression of E-selectin, inducing 
apoptosis.(18-21) Animal studies have shown that inducing 
apoptotic pathways limits lung inflammation.(6,7)
We aimed to determine the effects of blocking TNF-α 
by pretreatment with adalimumab before MV on clinical 
and histological parameters related to pulmonary edema.
METHODS
Animals and monitoring
We studied 18 adult male Wistar rats (mean weight: 
340 ± 15g) housed under controlled macro- and 
microenvironmental conditions with access to food 
and water ad libitum before the experiment. Rats were 
anesthetized with a combination of ketamine (80mg/Kg) 
and xylazine (20mg/kg) administered intraperitoneally. 
Then, lidocaine (10mg/kg) was applied as a local anesthetic 
in the subcutaneous tissue of the ventral neck region. 
After the appropriate depth of anesthesia was established, 
the animals were placed in a supine position on a heating 
pad to avoid hypothermia during the procedure. After 
an incision was made in the ventral neck region from 
the caudal jaw to the first third of the thorax, the left 
carotid artery and the right jugular vein were dissected 
and cannulated with 24G Teflon catheters. The arterial 
line was connected to the multiparameter monitor Dyne 
MCO-300-07 (Argentina) to measure mean arterial 
pressure (MAP) during the procedure. To maintain 
adequate hydration, the venous line was connected to an 
infusion pump administering a normal saline solution 
(10mL/h) throughout the study.
Rats were tracheotomized, and a cannula was 
introduced into the tracheostomy and connected to 
a mechanical ventilator (Neumovent GraphNet neo 
TECME ®).
Experimental protocol
The university’s Animal Research Ethics Committee 
approved the experimental protocol. After initial 
monitoring, all animals were ventilated for 20 minutes 
with the following settings: volume control ventilation, 
adjusting Vt to 8mL/kg, positive end-expiratory pressure 
(PEEP) of 5cmH2O, square wave, respiratory rate of 80 
breaths per minute and fraction of inspired oxygen (FiO2) 
of 0.40 without an inspiratory pause. The inspiratory 
time of 0.27 seconds and respiratory rate were adjusted 
afterwards to maintain the partial pressure of arterial 
carbon dioxide (PaCO2) between 45 - 55mmHg. Then, 
rats were randomized to one of three ventilation strategies: 
(1) the low Vt (LVt) group (n = 6): Vt of 8mL/kg and 
5cmH2O of PEEP, (2) High Vt (HVt) group (n = 6): Vt of 
35mL/kg and zero PEEP, or (3) pretreated HVt group (n 
= 6): adalimumab (100µg/kg, 50mg/mL in sterile water, 
diluted in a physiological solution to a concentration of 
500μg/mL(21)) administered by intraperitoneal injection 
24 hours before starting MV with a Vt of 35mL/kg and 
zero PEEP. The animals in the LVt and HVt groups were 
administered equivalent amounts of saline 24 hours 
before starting MV. After randomization, all animals were 
ventilated for 3 hours at a respiratory rate of 80 breaths 
per minute or with adjusting the respiratory frequency to 
maintain intended PaCO2 values, an FIO2 of 0.40 without 
an inspiratory pause, and the Vt and PEEP according to 
the group. When the Vt was increased for the animals 
in the HVt and pretreated HVt groups, dead space 
ventilation was increased to obtain comparable values  of 
PaCO2 among the three groups. At the end of MV, the 
rats were euthanized by exsanguination. Immediately after 
death, the lungs were removed; the left lung was instilled 
with 10% formaldehyde for histopathological study, and 
the right lower lobe was removed and weighed. The right 
lower lobe was placed in an oven at 60°C for 48 hours and 
weighed again; the difference between the wet weight and 
dry weight (W/D ratio) was calculated.
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Measurements and calculations
To measure PEEP, plateau pressure (Ppl), and Vt for 
the calculation of lung compliance [CL = Vt/Ppl - PEEP], 
we used neonatal lung transducers (Pulmonary Monitor 
CP-100, Bicore Monitoring Systems; Irvine, CA, USA). 
At 0 and 180 minutes, we measured MAP, Ppl, and Vt, 
and we used a portable blood analyzer (i-Stat Handheld, 
Abbot Inc.; Princeton, NJ, USA) to measure the partial 
pressure of arterial oxygen (PaO2), PCO2, and pH in blood 
from the carotid artery catheter.
Histological analysis
Three sections of each animal’s lungs from above and 
below the hilum were selected for histological analysis and 
stained with hematoxylin and eosin. A pathologist, who 
was blinded to treatment received, used the ATS 2010 Lung 
Injury Scoring System to assess the following parameters: 
(A) neutrophils in the alveolar space, (B) neutrophils in 
the interstitial space, (C) hyaline membrane formation, 
(D) intraalveolar proteinaceous material, and (E) alveolar 
septal thickening; score = [(20 × A) + (14 × B) + (7 × C) + 
(7 × D) + (2 × E)]/(number of 100× fields).(7)
Apoptosis
Two investigators used light microscopes at 40× 
magnification to evaluate two hematoxylin and eosin-
stained slides from each animal’s lungs to evaluate 
morphological criteria of apoptosis, defined as dense 
condensation of the nuclei of polymorphonuclear 
leukocytes or the presence of polymorphonuclear 
leukocytes inside macrophages. These findings are reported 
as the percentage of apoptotic cells.
Statistical analysis
Data are expressed as the mean ± standard deviation 
(SD). To compare variables among groups, we used 
ANOVA or Student’s t test as appropriate, considering 
p < 0.05 significant. Statistix 9 (Analytical Software; 
Tallahassee, FL, USA) was used for all analyses.
Graphics were performed using GraphPad software 
version 5.0 (San Diego, CA).
RESULTS
After 3 hours of MV, gross inspection showed that 
all lungs from the LVt group had a normal appearance, 
whereas the lungs from the HVt group had hemorrhage, 
congestion, and edema (Figure 1 C).
On microscopic inspection, the lungs in the HVt group 
showed alveolar and interstitial space polymorphonuclear 
leucocyte infiltration, with the presence of hyaline 
membranes and intraalveolar proteinaceous debris; 
detached alveolar coat cells; and fibrous intraalveolar 
walls during the process of repair (Figures 1B, 1C and 
3A). Low percentages of apoptotic bodies were seen in 
the LVt group and the pretreated HVt group (Figure 2B). 
The mean histological lung injury score was higher in the 
HVt group than in the LVt group (0.030 versus 0.0051, 
respectively, p = 0.003). The mean histological score was 
higher in the HVt group than in the pretreated HVt group 
(0.030 versus 0.0052, respectively, p = 0.003) (Figure 1A). 
The pretreated HVt group had an improved histological 
score, mainly due to a significant reduction in leukocyte 
infiltration. Worsening in thoracic system compliance in 
the HVt group and pretreated HVt group was seen at 3 
hours (p = 0.04) (Figure 3 and Table 1).
The W/D ratio in the HVt group was higher than that 
in the LVt group (p = 0.0001); the W/D ratio differed 
between the pretreated HVt group and HVt group (p = 
0.0001) (Table 2).
No statistically significant differences in hemodynamic 
parameters (MAP) or the PaO2 were observed between 
the pretreated HVt group and the HVt group (p = 0.42) 
(Figure 3). The partial pressure of arterial carbon dioxide 
did not differ between these two groups. At the end of the 
protocol, oxygenation tended to deteriorate in the HVt 
and pretreated HVt groups; the partial pressure of oxygen 
(PO2) remained significantly higher in the LVt group than 
in the HVt group (p = 0.018) and the  pretreated HVt 
group (p = 0.007) (Figure 3).
DISCUSSION
In this experimental study, the duration of MV was 
much shorter than that required by patients with lung 
injury; however, it is comparable with the MV time used 
in most published experimental VILI studies. We used 
two ventilation strategies: the LVt group was ventilated 
with a frequently used protective approach (Vt of 8mL/
kg and PEEP of 5cmH2O), which is generally considered 
harmless,(22) while the HVt and pretreated HVt groups 
were ventilated with a Vt of 35mL/kg and no PEEP, 
which is considered injurious. At randomization, the 
PaO2 was normal in all groups, suggesting that there was 
little or no lung injury at baseline. After 3 hours of MV, 
lung samples from the HVt group had diffuse alveolar 
damage, whereas those from the LVt group did not. In 
contrast, proportional changes in the PaO2/FiO2 and lung 
compliance were minor. These changes did not result 
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Figure 1 - Macro and microscopic evaluation of lungs. (A) Histological scores of the three groups: low tidal volume, high tidal volume, and adalimumab + high tidal volume. 
(B) Discrimination of the American Thoracic Society Lung Injury Scoring System variables. (C) Top images: light microscopy, hematoxylin and eosin, original magnification: 
40x. Left (low tidal volume group): normal lung architecture tissue. Middle (high tidal volume group): lungs with intraalveolar and interstitial leukocyte infiltration, hyaline 
membrane formation and septal thickening. Right (adalimumab + high tidal volume group): septal thickening with reduced leukocyte infiltration. Bottom pictures: Gross 
examination. Left (low tidal volume): normal lungs. Middle (high tidal volume): edema and hemorrhage. Right (adalimumab + high tidal volume): minimal congested areas. 
Vt - tidal volume; ADA - adalimumab; AST - alveolar septal tickening.
in increased compliance as expected, probably due to 
the short period of MV performed in this study, which 
may not reflect the expected pulmonary mechanical 
changes. Compared to the HVt group, the pretreated 
HVt group showed no significant differences with respect 
to oxygenation and pulmonary mechanics; however, 
histological findings driven by MV were minimized in the 
pretreated HVt group. Compared to the HVt group, the 
pretreated HVt group had lower histological lung injury 
due to decreased leukocyte infiltration into the alveolar 
space and pulmonary interstitium and a significant 
reduction hyaline membrane production, with similar 
impacts on septal thickening and proteinaceous material.
Adalimumab completely prevented structural lung 
injury and significantly decreased the histological lung 
injury score compared to HVt alone. Little apoptosis was 
observed in the adalimumab + HVt group (Figure 2A). 
Cell death occurs in two ways: necrosis and apoptosis. 
Necrosis can be observed when tissues become ischemic 
and the PaO2 falls drastically; this mechanism is probably 
less common in the lungs than in other tissues because of 
the double pulmonary circulation.(16,23-26)
In general, apoptosis occurs without the release of 
cellular products into the intercellular space, whereas 
necrosis is associated with cellular inflammation, ruptured 
membranes, and the release of intracellular products into 
the local environment. This process is extremely fast, so 
the number of apoptotic leukocytes visible in a swollen 
tissue is generally low and probably underestimates the 
actual degree of apoptosis(27) (Figure 2B). The destruction 
of the alveolar walls, the activation of fibroblasts, and the 
production of collagen lead to fibrosis during the repair 
process (Figure 2A).
We quantified the number of apoptotic 
polymorphonuclear leukocytes through their characteristic 
pattern of nuclear condensation after hematoxylin and 
eosin staining. The finding of apoptosis in the HVt group 
supports the argument that stimulation with TNF-α 
triggers a proinflammatory response as a proapoptotic 
signal.(28-30) In a mouse model, Bertok et al.(14) found 
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Figure 2 - Microscopic lung images (A) Detached alveolar coat cell (arrow) and fibrous intraalveolar walls in the process of repair (circle). Microscopic images from the 
adalimumab + high tidal volume group. (B) Apoptotic bodies recognized and digested by alveolar macrophages. This phenomenon is triggered by specific cell membrane 
receptors. Microscopic images from the adalimumab + high tidal volume group.
substantial improvement in the PaO2/FiO2 and 
permeability of the respiratory and alveolar barriers when 
an anti-TNF-α agent was administered intratracheally 
at the beginning of MV. In our study, we administered 
adalimumab intraperitoneally 24 hours before the 
beginning of MV. We decided to use this strategy because 
the absorption and distribution of adalimumab after 
subcutaneous administration of a single dose of 40mg in 
humans is slow, reaching peak plasma concentrations 5 
days after administration; we expected the intraperitoneal 
route to be faster, especially given the high metabolism of 
rats.
Moreover, intraperitoneally administered adalimumab 
has been shown to minimize the inflammatory response 
in an experimental model of pancreatitis in rats, and we 
chose our dose based on the results of that study.(20)
Tumor necrosis factor alpha is particularly important 
in lung injury because the lungs contain a large reservoir of 
cells producing TNF-α.(16) Our experiment was performed 
in healthy rats; the benefits of adalimumab may be even 
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Figure 3 - Monitoring during the experimental procedure. Changes in thoracic system compliance, mean arterial pressure and the partial pressure of arterial oxygen: 
ventilation with a high tidal volume was associated with decreased thoracic system compliance at 3 hours (p = 0.04), and comparison of the high tidal volume group 
versus the adalimumab + high tidal volume group showed no differences regarding lung compliance (p = 0,26). All groups presented a mean arterial pressure drop over 
the 3 hours of the study with no significant differences. Ventilation with a high tidal volume was associated with hypoxemia compared with ventilation with a low tidal 
volume (p = 0.018), while the adalimumab-treated group showed no statistically significant differences at 3 hours compared with the high tidal volume group (p = 0.42). 
MAP - mean arterial pressure; PaO2 - partial pressure of arterial oxygen; Vt - tidal volume; TNF-α - tumor necrosis factor alpha.
Table 1 - Compliance analysis: lung compliance in the three groups (low tidal 
volume, high tidal volume, and adalimumab + high tidal volume) at baseline and 
3 hours after intervention
Baseline 3 hours
Low Vt 0.61 ± 0.08 0.53 ± 0.05
High Vt 0.54 ± 0.05 0.44 ± 0.06
High Vt + ADA 0.57 ± 0.08 0.54 ± 0.17
Vt - tidal volume; ADA - adalimumab. Compliance is expressed as the average ± standard 
deviation (N = 6 per group).
Table 2 - Lung edema evaluation
1 2 3 4 5 6
Low Vt 0.05 0.067 0.033 0041 0.052 0.037
High Vt 4.40 4.91 3.92 4.20 4.78 4.41
High Vt + ADA 1.51 1.83 1.28 1.42 1.60 1.52
3 hours
Low Vt 0.046 ± 0.012
High Vt 4.43 ± 0.36
High Vt + ADA 1.51 ± 0.18
The ratio of wet weight to dry weight in the high tidal volume group was higher than that in the low tidal volume group; the ratio of wet weight to dry weight differed between the adalimumab 
+ high tidal volume group and the high tidal volume group. Vt - tidal volume; ADA - adalimumab. The wet weight-to-dry weight ratio is expressed as the average ± standard deviation (N = 6 
per group).
greater in humans who require prolonged MV treatment. 
Infliximab and adalimumab, although sharing the same 
mechanism of action, are different molecules, and 
infliximab has been studied in rats and shown to minimize 
pulmonary fibrosis due to bleomycin. In our study, lung 
injury associated with volutrauma was minimized in rats 
who underwent MV.(28)
In the present study, PaO2/FiO2 levels were similar in 
the LVt group and the HVt group, probably because the 
period of MV was too short to affect oxygenation. A longer 
experimental period may show a difference between these 
two groups and a difference between the HVt group and 
the pretreated HVt group.
Retrospectively, as limitations of this study, we 
could have measured the levels of other inflammatory 
mediators that could be affected by inhibiting TNF-α. 
Another limitation related to apoptosis analysis is the 
lack of quantitative measurement methods (e.g., TUNEL 
staining) that may have better characterized apoptosis in 
this study.
A clinical trial with intravenous anti-TNF-α antibody 
administration in patients with septic shock found no 
clinical benefit,(31) but a recent meta-analysis suggests that 
immunotherapy with a monoclonal anti-TNF-α antibody 
in patients with sepsis reduces overall mortality and anti-
TNF-α therapy may improve survival in patients with 
shock.(32) The association between lung injury and sepsis 
represents an opportunity for the use of these drugs.
Studying the hypothesis that patients previously treated 
with adalimumab or similar immunomodulators have a 
reduced risk of VILI may create a window of opportunity 
for other clinical applications, and these findings may 
contribute to the understanding of the pathophysiology 
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of lung injury. Additionally, these findings may help in 
situations where there is a high risk of lung injury during 
elective surgeries, such as lung transplant or prolonged 
MV supported surgeries.
CONCLUSION
Intraperitoneal administration of adalimumab 
24 hours before injurious mechanical ventilation 
significantly reduced ventilator-induced lung injury in 
this experimental rat model. This reduction was associated 
with hemodynamic improvement but had no impact on 
oxygenation or lung compliance. Adalimumab prevented 
the recruitment of polymorphonuclear leukocytes into the 
alveoli and pulmonary interstitium. Inhibition of tumor 
necrosis factor alpha may be a promising adjunctive 
approach to protective ventilation in an attempt to avoid 
ventilator-induced lung injury.
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Objetivo: Determinar se a administração de adalimumabe 
previamente à ventilação mecânica reduz a lesão pulmonar indu-
zida por ventilação mecânica.
Métodos: Randomizaram-se 18 ratos em três grupos 
submetidos à ventilação mecânica por 3 horas com uma fração 
inspirada de oxigênio de 0,40%. Os três grupos foram assim 
caracterizados: um grupo com baixo volume corrente (n = 6), 
no qual se utilizaram volume corrente de 8mL/kg e pressão 
expiratória final positiva de 5cmH2O; um grupo com alto 
volume corrente (n = 6), no qual se utilizaram volume corrente 
de 35mL/kg e pressão expiratória final positiva de zero; e um 
grupo pré-tratado com alto volume corrente (n = 6), no qual se 
administraram adalimumabe (100µg/kg) por via intraperitoneal 
24 horas antes do início da ventilação mecânica, volume corrente 
de 35mL/kg e pressão expiratória final positiva de zero. Realizou-
se ANOVA para comparação de dano histológico (com utilização 
de escores segundo o ATS 2010 Lung Injury Scoring System), 
edema pulmonar, complacência pulmonar, pressão parcial de 
oxigênio arterial e pressão arterial média entre os grupos.
RESUMO
Descritores: Adalimumabe/administração & dosagem; 
Respiração artificial; Insuficiência respiratória; Lesão pulmonar 
induzida por ventilação mecânica
Resultados: Após 3 horas de ventilação, o escore médio 
de lesão histológica pulmonar foi mais elevado no grupo 
com alto volume corrente do que no grupo com baixo 
volume corrente (0,030 versus 0,0051; p = 0,003). O 
grupo com alto volume corrente demonstrou complacência 
pulmonar diminuída após 3 horas (p = 0,04) e hipoxemia 
(p = 0,018 versus controle). O grupo alto volume corrente 
tratado previamente teve melhora do escore histológico, 
principalmente devido à redução significante da infiltração 
leucocitária (p = 0,003).
Conclusão: O exame histológico após 3 horas de 
ventilação lesiva revelou lesão pulmonar induzida por 
ventilação mecânica na ausência de modificações mensuráveis 
na mecânica pulmonar e na oxigenação; a administração 
de adalimumabe antes da ventilação mecânica diminuiu o 
edema pulmonar e o dano histológico.
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